Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Comparative susceptibilities of Campylobacter pylori to norfloxacin and other agents.

Literature DB >> 3619429

Comparative susceptibilities of Campylobacter pylori to norfloxacin and other agents.

D L Shungu, D R Nalin, R H Gilman, H H Gadebusch, A T Cerami, C Gill, B Weissberger.

Abstract

Twenty-one strains of Campylobacter pylori (Campylobacter pyloridis) were tested for susceptibility to norfloxacin and other agents by the serial agar dilution method. Ampicillin (MIC for 90% of isolates [MIC90], 0.016 micrograms/ml) and famotidine (MIC90, greater than 1,024 micrograms/ml) were, respectively, the most and the least active of the agents tested. Norfloxacin (MIC90, 1 microgram/ml) and imipenem (MIC90, 0.125 micrograms/ml) were substantially active against this organism.

Entities: Chemical Species

Mesh：

Substances：

Year: 1987 PMID： 3619429 PMCID： PMC284219 DOI： 10.1128/AAC.31.6.949

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

10 in total

1. Susceptibility of clinical isolates of Campylobacter pyloridis to 11 antimicrobial agents.

Authors: C A McNulty; J Dent; R Wise
Journal: Antimicrob Agents Chemother Date: 1985-12 Impact factor: 5.191

2. Relation of Campylobacter pyloridis to gastritis and peptic ulcer.

Authors: G E Buck; W K Gourley; W K Lee; K Subramanyam; J M Latimer; A R DiNuzzo
Journal: J Infect Dis Date: 1986-04 Impact factor: 5.226

3. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration.

Authors: B J Marshall; J R Warren
Journal: Lancet Date: 1984-06-16 Impact factor: 79.321

4. Urea hydrolysis in patients with Campylobacter pyloridis infection.

Authors: B J Marshall; S R Langton
Journal: Lancet Date: 1986-04-26 Impact factor: 79.321

5. Antibiotic sensitivity of "Campylobacter pylori".

Authors: G Kasper; N Dickgiesser
Journal: Eur J Clin Microbiol Date: 1984-10 Impact factor: 3.267

6. Characterization of "Campylobacter pyloridis" by culture, enzymatic profile, and protein content.

Authors: F Megraud; F Bonnet; M Garnier; H Lamouliatte
Journal: J Clin Microbiol Date: 1985-12 Impact factor: 5.948

Review 7. Norfloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors: B Holmes; R N Brogden; D M Richards
Journal: Drugs Date: 1985-12 Impact factor: 9.546

8. Pyloric Campylobacter infection and gastroduodenal disease.

Authors: B J Marshall; D B McGechie; P A Rogers; R J Glancy
Journal: Med J Aust Date: 1985-04-15 Impact factor: 7.738

9. The minimum inhibitory and bactericidal concentrations of antibiotics and anti-ulcer agents against Campylobacter pyloridis.

Authors: C S Goodwin; P Blake; E Blincow
Journal: J Antimicrob Chemother Date: 1986-03 Impact factor: 5.790

Review 10. Famotidine. Pharmacodynamic and pharmacokinetic properties and a preliminary review of its therapeutic use in peptic ulcer disease and Zollinger-Ellison syndrome.

Authors: D M Campoli-Richards; S P Clissold
Journal: Drugs Date: 1986-09 Impact factor: 9.546

10 in total

11 in total

1. Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori.

Authors: T Iwahi; H Satoh; M Nakao; T Iwasaki; T Yamazaki; K Kubo; T Tamura; A Imada
Journal: Antimicrob Agents Chemother Date: 1991-03 Impact factor: 5.191

Review 2. Mechanisms of antibiotic resistance in Campylobacter species.

Authors: D E Taylor; P Courvalin
Journal: Antimicrob Agents Chemother Date: 1988-08 Impact factor: 5.191

3. Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents.

Authors: M L Grayson; G M Eliopoulos; M J Ferraro; R C Moellering
Journal: Eur J Clin Microbiol Infect Dis Date: 1989-10 Impact factor: 3.267

4. Comparative in vitro activities of six new fluoroquinolones and other oral antimicrobial agents against Campylobacter pylori.

Authors: A E Simor; S Ferro; D E Low
Journal: Antimicrob Agents Chemother Date: 1989-01 Impact factor: 5.191

5. Treatment failure of norfloxacin against Campylobacter pylori and chronic gastritis in patients with nonulcerative dyspepsia.

Authors: J C Mertens; W Dekker; E E Ligtvoet; P Blok
Journal: Antimicrob Agents Chemother Date: 1989-02 Impact factor: 5.191

Review 6. Campylobacter pylori and gastroduodenal disease.

Authors: G E Buck
Journal: Clin Microbiol Rev Date: 1990-01 Impact factor: 26.132

7. Antibacterial properties of lansoprazole alone and in combination with antimicrobial agents against Helicobacter pylori.

Authors: M Nakao; M Tada; K Tsuchimori; M Uekata
Journal: Eur J Clin Microbiol Infect Dis Date: 1995-05 Impact factor: 3.267

Review 8. Fluoroquinolone antibiotics. Microbiology, pharmacokinetics and clinical use.

Authors: J H Paton; D S Reeves
Journal: Drugs Date: 1988-08 Impact factor: 9.546

Review 9. A risk-benefit assessment of drugs used in the eradication of Helicobacter pylori infection.

Authors: A Hackelsberger; P Malfertheiner
Journal: Drug Saf Date: 1996-07 Impact factor: 5.606

10. Effect of pH variation on the susceptibility of Helicobacter pylori to three macrolide antimicrobial agents and temafloxacin.

Authors: G J Malanoski; G M Eliopoulos; M J Ferraro; R C Moellering
Journal: Eur J Clin Microbiol Infect Dis Date: 1993-02 Impact factor: 3.267